Expert reflections on the optimal identification and management of unresectable hepatocellular carcinoma given recent updates from the IMbrave150 trial.
EP. 1: Approaching the Identification and Management of HCC
Expert Richard Kim, MD, reflects on the nature of HCC, particularly the challenges inherent in diagnosis and management.
EP. 2: Unresectable HCC: Selecting the Optimal Frontline Therapy
A comprehensive overview of the frontline treatment landscape for patients with unresectable HCC, including those who present with contraindications to standard-of-care therapy.
EP. 3: Advice on Molecular Testing and Sequencing in Unresectable HCC
A brief synopsis on optimal sequencing strategies for patients who have been diagnosed with unresectable hepatocellular carcinoma.
EP. 4: IMbrave150: Frontline Atezolizumab + Bevacizumab in Unresectable HCC
Richard Kim, MD, shares insight on positive results from IMbrave150, which tested the frontline combination of atezolizumab and bevacizumab in patients with unresectable HCC.
EP. 5: Looking Toward the Future Management of Unresectable HCC
Considerations for ongoing clinical trials that may shape the future treatment landscape of unresectable hepatocellular carcinoma.
2 Clarke Drive Cranbury, NJ 08512